NOVAREX Co.,Ltd. (KOSDAQ:194700)
9,560.00
-190.00 (-1.95%)
At close: Oct 23, 2026
NOVAREX Revenue
In the year 2025, NOVAREX had annual revenue of 404.26B KRW with 35.78% growth. NOVAREX had revenue of 100.65B in the quarter ending December 31, 2025, with 22.52% growth. That makes NOVAREX the 14,425th largest company in the world by revenue and 710th in South Korea.
Revenue
404.26B
Revenue Growth
+35.78%
P/S Ratio
0.41
Revenue / Employee
871.25M
Employees
464
Market Cap
164.45B
Revenue by Geography
- South Korea 261.70B 64.7%
- Asia 135.28B 33.5%
- USA 7.02B 1.7%
- Others 267.04M 0.1%
Fiscal year ended Dec 31, 2025 See the full NOVAREX breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 404.26B | 106.53B | 35.78% |
| Dec 31, 2024 | 297.73B | -4.44B | -1.47% |
| Dec 31, 2023 | 302.17B | 20.49B | 7.28% |
| Dec 31, 2022 | 281.68B | 2.89B | 1.04% |
| Dec 31, 2021 | 278.79B | 55.96B | 25.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ahn-Gook Pharmaceutical | 345.08B |
| Cosmax Nbt | 335.18B |
| Kyung Dong Pharmaceutical | 201.12B |
| GC WellBeing | 192.21B |
| DAE HWA Pharmaceutical | 148.75B |
| HYUNDAI BIOLAND | 140.70B |
| OPTUS Pharmaceutical | 94.47B |
| Vivozon Pharmaceutical | 50.34B |